Improved survival in pediatric acute lymphoblastic leukemia through therapy intensification based on minimal residual disease and protocol-driven early response risk classification
Hyery Kim1, Su Hyun Yoon2, Sunghan Kang2
1Department of Pediatrics, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea. taban@hanmail.net.
Insights
Minimal residual disease (MRD) monitoring and intensified therapy significantly improve survival for pediatric acute lymphoblastic leukemia (ALL). This approach optimizes risk-adapted treatment strategies, leading to better outcomes for both standard-risk and high-risk patients.
Area of Science:
- Pediatric Oncology
- Hematologic Malignancies
- Clinical Trial Analysis
Background:
- Minimal residual disease (MRD) guided therapy is the standard for pediatric acute lymphoblastic leukemia (ALL).
- Risk stratification and treatment intensification are crucial for optimizing patient outcomes.
- Understanding the interplay between MRD levels and risk groups is essential for refining treatment protocols.
Purpose of the Study:
- To assess the impact of MRD-driven treatment intensification in pediatric ALL.
- To evaluate the effectiveness of MRD-guided therapy in conjunction with protocol-defined risk groups.
- To determine if intensified therapy improves survival outcomes in pediatric ALL patients.
Main Methods:
- Retrospective analysis of 209 pediatric ALL patients treated between 2013 and 2023.
- MRD assessment using flow cytometry at critical treatment junctures.
- Treatment intensification based on MRD levels (≥0.1%) and risk stratification (NCI, cytogenetics).
Main Results:
- Overall 5-year survival rates were 92.5% (OS) and 84.3% (EFS).
- Treatment intensification significantly improved event-free survival (EFS) in high MRD patients (94.2% vs. 75.5%, p=0.04).
- MRD-based intensification eliminated survival differences between rapid and slow early responders and improved outcomes in post-induction high MRD patients.
Conclusions:
- MRD-guided therapy intensification markedly improves survival outcomes in pediatric ALL.
- Combining MRD monitoring with risk-based protocols optimizes risk-adapted treatment strategies.
- MRD monitoring is vital for tailoring therapy and improving survival in pediatric ALL.
Purpose:
Minimal residual disease (MRD)-guided therapy is the global standard treatment for pediatric acute lymphoblastic leukemia (ALL). We assessed the impact of MRD-driven intensification along with protocol-defined risk groups in pediatric ALL treatment.
Methods:
This retrospective analysis included 209 patients with ALL (treated between January 2013 to June 2023). MRD was assessed using six- to eight-color flow cytometry at the end of each phase before the maintenance phase. Post-induction treatment was determined based on early response, National Cancer Institute risk, and cytogenetics. High-risk (HR) patients followed the Korean HR or CCG-1882 protocols and standard-risk (SR) patients followed the modified COG-AALL0331 protocol. Treatment was intensified if flow-MRD ≥ 0.1% was identified.
Results:
Overall, 103 and 106 patients were classified as having SR and HR, respectively. The 5-year overall survival (OS) and event-free survival (EFS) were 92.5% and 84.3%, respectively. Thirty SR and 18 HR patients received intensified chemotherapy. Treatment intensification significantly improved EFS in patients with high MRD (94.2% vs. 75.5%, p = 0.04), particularly in post-induction patients with high MRD (90.0% vs. 19.0%, p = 0.035). The difference in survival between rapid early responder (RER) and slow early responder (SER) groups was eliminated after MRD-based intensification. The implementation rates of treatment intensification varied over time (9.1% before 2015, 28.6% during 2016-2019, and 13.9% during 2020-2023), reflecting improved risk stratification and therapy selection.
Conclusion:
MRD-guided therapy intensification markedly improved survival outcomes in patients with pediatric ALL when combined with risk-based protocols, highlighting the importance of MRD monitoring for optimizing risk-adapted treatment strategies.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:56Treatment Resistant Cancers